Piotr Nieczypor

This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Volastra Therapeutics, Inc., Laboratorios Del Dr. Esteve S.a.. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Piotr Nieczypor. Retrieved from https://idiyas.com/inventor/piotr-nieczypor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 3 (Patent Applications = 4)

% Patents Active = 66.7

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 4.7

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

2 out of 3

Volastra Therapeutics, Inc.

patents

1 out of 150

Laboratorios Del Dr. Esteve S.a.

patents

Years Active: 2017-2024

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091412 - Heterocyclic inhibitors of ENPP1 (2024-09-17),

2. 11780849 - Imino sulfanone inhibitors of ENPP1 (2023-10-10),

3. 9676784 - Fused imidazolyl derivatives, their preparation and use as medicaments (2017-06-13),

Title: Piotr Nieczypor: Innovator in ENPP1 Inhibition

Introduction

Piotr Nieczypor is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of medicinal chemistry, particularly in the development of inhibitors for ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). With a total of 3 patents, his work focuses on innovative compounds that have the potential to treat diseases mediated by ENPP1.

Latest Patents

Nieczypor's latest patents include groundbreaking research on heterocyclic inhibitors of ENPP1. This patent discusses triazolopyrimidine and imidazolopyrimidine inhibitors, detailing their compositions and methods of use for treating related diseases. Another significant patent involves imino sulfanone inhibitors of ENPP1, which highlights sulfoximine-based inhibitors and their therapeutic applications. These patents reflect his commitment to advancing medical science through innovative solutions.

Career Highlights

Throughout his career, Piotr Nieczypor has worked with prominent companies such as Volastra Therapeutics, Inc. and Laboratorios Del Dr. Esteve S.A. His experience in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his contributions to medicinal chemistry.

Collaborations

Some of his notable coworkers include Derek A. Cogan and Sarah Bettigole. Their collaborative efforts have played a crucial role in the development of his innovative patents and research.

Conclusion

Piotr Nieczypor stands out as a significant figure in the realm of ENPP1 inhibition, with a focus on developing effective therapeutic agents. His patents and collaborations reflect a dedication to advancing healthcare through innovative research.

Profile summary based on public USPTO records.